US equities
|
SPCX
$167.39
▲+5.30%
NVDA
$236.34
▲+1.02%
MU
$1,067.04
▼-0.73%
TSLA
$378.30
▲+2.08%
MSFT
$526.48
▲+1.73%
SNDK
$1,710.80
▼-0.53%
INTC
$117.43
▼-1.59%
META
$744.40
▲+2.24%
SPCX
$167.39
▲+5.30%
NVDA
$236.34
▲+1.02%
MU
$1,067.04
▼-0.73%
TSLA
$378.30
▲+2.08%
MSFT
$526.48
▲+1.73%
SNDK
$1,710.80
▼-0.53%
INTC
$117.43
▼-1.59%
META
$744.40
▲+2.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
LeMaitre Vascular, Inc. - Common Stock
(NQ:
LMAT
)
81.64
+2.69 (+3.40%)
Delayed Quote
Updated: 12:45 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LeMaitre Vascular, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
3 Small-Cap Stocks We Steer Clear Of
September 22, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via
StockStory
2 Profitable Stocks to Target This Week and 1 We Ignore
September 21, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
Topics
Supply Chain
3 Out-of-Favor Stocks with Questionable Fundamentals
September 04, 2026
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...
Via
StockStory
Q2 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
August 12, 2026
Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - special...
Via
StockStory
Topics
Artificial Intelligence
Economy
LeMaitre Vascular (NASDAQ:LMAT) Shares Slide on Q2 Earnings Miss
↗
August 04, 2026
Via
Chartmill
LeMaitre Vascular Inc. (NASDAQ:LMAT) Passes the Quality Test with Caviar Cruise Screen
↗
June 24, 2026
Via
Chartmill
LeMaitre Vascular Inc (NASDAQ:LMAT): A Quality Investing Candidate Passing All Caviar Cruise Screen Tests
↗
May 13, 2026
Via
Chartmill
LeMaitre Vascular (NASDAQ:LMAT) Reports Steady Q1 2026 Results with Earnings Beat and In-Line Revenue
↗
May 05, 2026
Via
Chartmill
Topics
Earnings
LeMaitre Vascular (LMAT) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
Artegraft sales surged 34% as gross margins expanded to 72.1%.
Via
The Motley Fool
Topics
Earnings
The Top 5 Analyst Questions From LeMaitre’s Q2 Earnings Call
August 11, 2026
LeMaitre’s second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and As...
Via
StockStory
Topics
Earnings
Stocks making big moves yesterday: LeMaitre, ePlus, Booking, Paymentus, and Vishay Intertechnology
August 06, 2026
Check out the companies making headlines yesterday: LeMaitre (NASDAQ:LMAT): Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell by 18.6% on Wednesday...
Via
StockStory
Topics
Earnings
Minervini Watchlist April 24, 2026 - Before Market Open
↗
April 24, 2026
Via
Chartmill
Why LeMaitre (LMAT) Shares Are Getting Obliterated Today
August 05, 2026
What Happened? Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 18.6% in the morning session after the company reported second-quarter r...
Via
StockStory
Topics
Artificial Intelligence
LMAT Q2 Deep Dive: International Growth and Supply Constraints Shape Results
August 05, 2026
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 mil...
Via
StockStory
LeMaitre Vascular Q2 Earnings Call Highlights
↗
August 04, 2026
LeMaitre Vascular (NASDAQ:LMAT) reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign...
Via
MarketBeat
Topics
Earnings
LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6%
August 04, 2026
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 mil...
Via
StockStory
LeMaitre (LMAT) Reports Earnings Tomorrow: What To Expect
August 02, 2026
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here’s what you need to know. LeM...
Via
StockStory
Topics
Artificial Intelligence
1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds
July 10, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Topics
Energy
1 High-Flying Stock to Target This Week and 2 Facing Headwinds
July 02, 2026
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...
Via
StockStory
Topics
Initial Public Offering
1 Russell 2000 Stock with Exciting Potential and 2 We Find Risky
June 29, 2026
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
Via
StockStory
Topics
Firearms
3 of Wall Street’s Favorite Stocks We Find Risky
June 02, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via
StockStory
Topics
Electric Vehicles
1 Reason to Avoid LMAT and 1 Stock to Buy Instead
May 21, 2026
LeMaitre has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 15.5% to $101.53 ...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Supply Chain
Winners And Losers Of Q1: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
May 18, 2026
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, includ...
Via
StockStory
Topics
Artificial Intelligence
Economy
3 Healthcare Stocks with Open Questions
May 14, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...
Via
StockStory
Topics
Retirement
5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call
May 12, 2026
LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns o...
Via
StockStory
Topics
Earnings
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
May 07, 2026
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...
Via
StockStory
LMAT Q1 Deep Dive: Artegraft Expansion and Pricing Drive, Margin Upside Meets Cautious Market
May 06, 2026
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio...
Via
StockStory
LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
May 05, 2026
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio...
Via
StockStory
LeMaitre (LMAT) Q1 Earnings Report Preview: What To Look For
May 03, 2026
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market hours. Here’s what you need to know. LeMaitre beat...
Via
StockStory
Topics
Artificial Intelligence
3 Hyped Up Stocks Walking a Fine Line
April 22, 2026
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...
Via
StockStory
< Previous
1
2
3
4
5
6
7
Next >
